Amerikanische Gesellschaft für Hirudotherapie

A novel trypsin Kazal-type inhibitor from Aedes aegypti with thrombin coagulant inhibitory activity

Biochemistry paper published in Biochimie (2010)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenomik & ProteomikSpeichel-PharmakologieWatanabe RM et al. · Biochimie, 2010

Abstract

Kazal-type inhibitors play several important roles in invertebrates, such as anticoagulant, vasodilator and antimicrobial activities. Putative Kazal-type inhibitors were described in several insect transcriptomes. In this paper we characterized for the first time a Kazal unique domain trypsin inhibitor from the Aedes aegypti mosquito. Previously, analyses of sialotranscriptome of A. aegypti showed the potential presence of a Kazal-type serine protease inhibitor, in female salivary glands, carcass and also in whole male, which we named AaTI (A. aegypti trypsin inhibitor). AaTI sequence showed amino acid sequence similarity with insect thrombin inhibitors, serine protease inhibitor from Litopenaeus vannamei hemocytes and tryptase inhibitor from leech Hirudo medicinalis (LDTI). In this work we expressed, purified and characterized the recombinant AaTI (rAaTI). Molecular weight of purified rAaTI was 7 kDa rAaTI presented dissociation constant (K(i)) of 0.15 and 3.8 nM toward trypsin and plasmin, respectively, and it weakly inhibited thrombin amidolytic activity. The rAaTI was also able to prolong prothrombin time, activated partial thromboplastin time and thrombin time. AaTI transcription was confirmed in A. aegypti female salivary gland and gut 3 h and 24 h after blood feeding, suggesting that this molecule can act as anticoagulant during the feeding and digestive processes. Its transcription in larvae and pupae suggested that AaTI may also play other functions during the mosquito's development.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAedesAmino Acid SequenceAnimalsAnticoagulantsBase SequenceCloning, MolecularDNA, ComplementaryMolecular Sequence DataRecombinant ProteinsSequence Homology, Amino AcidThrombinTrypsin Inhibitors

Zusammenfassung

Kazal-type inhibitor AaTI from Aedes aegypti sialotranscriptome shows sequence similarity to leech Hirudo medicinalis tryptase inhibitor LDTI — supports the conservation of hematophagy-associated anti-coagulation proteins across phyla.

Warum dies für die Hirudotherapie relevant ist

This study characterized AaTI, a novel Kazal-type trypsin inhibitor from the mosquito Aedes aegypti, which showed amino acid sequence similarity with insect thrombin inhibitors and the tryptase inhibitor LDTI from the leech Hirudo medicinalis. The recombinant AaTI (7 kDa) inhibited trypsin (Ki 0.15 nM) and plasmin (Ki 3.8 nM), weakly inhibited thrombin amidolytic activity, and prolonged prothrombin time, activated partial thromboplastin time, and thrombin time. The relevance to ASH's domain is indirect: the study identifies a structural and functional class of serine protease inhibitors (Kazal-type) that includes leech-derived molecules like LDTI, suggesting shared molecular strategies across hematophagous invertebrates for facilitating blood feeding through anticoagulation. Caveat: This study concerns a mosquito protein, not leeches or leech-derived substances; the leech connection is limited to sequence homology, and no leech secretome components were isolated, tested, or characterized.

Zitation

A novel trypsin Kazal-type inhibitor from Aedes aegypti with thrombin coagulant inhibitory activity.

Watanabe RM et al. · Biochimie, 2010

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.